Clinical Studies and Therapies in Parkinson s Disease

Produk Detail:
  • Author : Juan Segura-Aguilar
  • Publisher : Academic Press
  • Pages : 200 pages
  • ISBN : 9780128221204
  • Rating : /5 from reviews
CLICK HERE TO GET THIS BOOK >>>Clinical Studies and Therapies in Parkinson s Disease

Download or Read online Clinical Studies and Therapies in Parkinson s Disease full in PDF, ePub and kindle. this book written by Juan Segura-Aguilar and published by Academic Press which was released on 15 September 2021 with total page 200 pages. We cannot guarantee that Clinical Studies and Therapies in Parkinson s Disease book is available in the library, click Get Book button and read full online book in your kindle, tablet, IPAD, PC or mobile whenever and wherever You Like. More than 50 years have passed since the use of L-dopa in the palliative treatment of Parkinson's Disease, and it remains as the most common treatment despite the fact that after 4-6 years it induces severe side effects such as dyskinesia. Numerous preclinical investigations based on endogenous neurotoxin models have promised various therapies in Parkinson's disease, but efforts have failed at the time of transferring these successful results to preclinical studies. Although there are several publications that warn of these failures, the scientific community remains mostly unaware, and there is a need to focus their efforts on potential therapeutics that can slow the development of the disease. Translation of Preclinical Models to Clinical Studies and Therapies in Parkinson's Disease: Translations from Preclinical Models analyses why preclinical models based on exogenous neurotoxins have failed. To develop new pharmacological treatments for Parkinson ́s Disease, the book discusses a more physiological model directly related to metabolism of dopaminergic neurons that are lost before and after the onset of the disease. This book also reviews genetic preclinical models based on genetic mutations associated with the familial form of the disease and preclinical models based on endogenous neurotoxins. Analyses why preclinical models of Parkinson's Disease therapies based on exogenous neurotoxins have failed Proposes a more physiological model directly related to metabolism of dopaminergic neurons Reviews genetic preclinical models based on genetic mutations and preclinical models based on endogenous neurotoxins

Clinical Studies and Therapies in Parkinson s Disease

Clinical Studies and Therapies in Parkinson s Disease
  • Author : Juan Segura-Aguilar
  • Publisher : Academic Press
  • Release : 15 September 2021
GET THIS BOOK Clinical Studies and Therapies in Parkinson s Disease

More than 50 years have passed since the use of L-dopa in the palliative treatment of Parkinson's Disease, and it remains as the most common treatment despite the fact that after 4-6 years it induces severe side effects such as dyskinesia. Numerous preclinical investigations based on endogenous neurotoxin models have promised various therapies in Parkinson's disease, but efforts have failed at the time of transferring these successful results to preclinical studies. Although there are several publications that warn of these failures,

Neurorehabilitation in Parkinson s Disease

Neurorehabilitation in Parkinson s Disease
  • Author : Marilyn Trail,Elizabeth J. Protas,Eugene C. Lai
  • Publisher : SLACK Incorporated
  • Release : 09 May 2021
GET THIS BOOK Neurorehabilitation in Parkinson s Disease

'Neurorehabilitation in Parkinson's Disease' serves as a reference for the treatment of patients with Parkinson's disease. In addition to providing treatment models for physical therapy, occupational therapy, & speech-language pathology, the text covers topics such as review of pathophysiology, & symptomatology.

Therapy of Parkinson s Disease

Therapy of Parkinson s Disease
  • Author : William C. Koller,George W. Paulson
  • Publisher : CRC PressI Llc
  • Release : 09 May 1995
GET THIS BOOK Therapy of Parkinson s Disease

This work offers a comprehensive and fully updated overview of supportive patient management strategies, highlighting therapeutic approaches other that dopaminergic agents and conventional antiparkinsonian drugs. This second edition: reviews the neuroprotective effects of selegiline on Parkinson's disease; investigates ways of enhancing the effectiveness of levodopa-based therapy; presents methods of speech therapy with well-documented short- and long-term efficacy; and more.

The New Parkinson s Disease Treatment Book

The New Parkinson s Disease Treatment Book
  • Author : J. Eric Ahlskog (MD, PhD.),J. Eric Ahlskog
  • Publisher : Oxford University Press, USA
  • Release : 06 August 2015
GET THIS BOOK The New Parkinson s Disease Treatment Book

As many as one million Americans, including Michael J. Fox and Muhammad Ali, suffer from Parkinson's Disease. Now, a leader in the fight against Parkinson's, Dr. J. Eric Ahlskog of the Mayo Clinic, has revised and updated his definitive guide for patients and their families. Dr. Ahlskog offers a crystal-clear, nuts-and-bolts approach to the treatment of PD, distilled from more than 30 years of experience as a clinician and researcher. His goal is to educate patients so that they can better

Neurological Rehabilitation

Neurological Rehabilitation
  • Author : Darcy Ann Umphred
  • Publisher : Mosby
  • Release : 09 May 2021
GET THIS BOOK Neurological Rehabilitation

Includes everything from basic theories to the breakthroughs in screening, treatments, diagnosis, and interventions, this edition is the neurology book for therapy students and clinicians. It takes a problem-solving approach to the therapeutic management of movement limitations, quality of life, and more.